Sitravatinib Plus Pembrolizumab in Patients With Advanced Treatment-Naïve PD-L1+ Non-Squamous NSCLC
Phase 2
Terminated
- Conditions
- Lung NeoplasmsMetastatic Lung Non-Small Cell CarcinomaSitravatinibCarcinoma, Non-Small-Cell LungPD-L1 Gene MutationAdvanced Treatment-Naïve PD-L1Lung DiseasesStage IV Lung Non-Small Cell Cancer AJCC v7Pembrolizumab
- Interventions
- First Posted Date
- 2021-06-14
- Last Posted Date
- 2025-04-17
- Lead Sponsor
- Sarah Goldberg
- Target Recruit Count
- 9
- Registration Number
- NCT04925986
- Locations
- 🇺🇸
Yale University, New Haven, Connecticut, United States
© Copyright 2025. All Rights Reserved by MedPath